Smith & Nephew (LON:SN) Price Target Cut to GBX 1,250 by Analysts at Berenberg Bank

Smith & Nephew (LON:SN) had its price objective trimmed by Berenberg Bank from GBX 1,300 to GBX 1,250 in a research note issued to investors on Friday, MarketBeat Ratings reports. The brokerage currently has a hold rating on the stock.

Other equities analysts have also issued research reports about the stock. Citigroup lowered shares of Smith & Nephew to a “buy” rating in a report on Friday, July 10th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 1,500 price target on shares of Smith & Nephew in a research note on Wednesday, August 5th. Royal Bank Of Canada cut their price target on shares of Smith & Nephew from GBX 1,350 to GBX 1,250 and set a “sector perform” rating for the company in a research report on Thursday, August 6th. JPMorgan Chase & Co. reduced their price objective on Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating on the stock in a research note on Thursday, August 6th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 1,400 price objective on shares of Smith & Nephew in a report on Thursday, July 30th. Three analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of GBX 1,310.

Smith & Nephew Price Performance

Shares of LON SN opened at GBX 1,096 on Friday. The company has a market capitalization of £12.02 billion, a PE ratio of 39.46, a P/E/G ratio of 0.46 and a beta of 0.69. The company’s 50 day simple moving average is GBX 1,135.10 and its 200 day simple moving average is GBX 1,188.50. The company has a debt-to-equity ratio of 73.07, a current ratio of 2.14 and a quick ratio of 0.84.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.